How Long Does Kymriah Stay in a Patient's System?
Kymriah, also known as tisagenlecleucel, is a type of immunotherapy drug used to treat certain types of blood cancers, such as B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
What Happens After Administration?
When administered, Kymriah is taken up by cells in the patient's body, where it is activated and begins to stimulate a patient's immune system to attack cancer cells [1]. The exact duration of Kymriah in a patient's system is not well-established, but studies have shown that it can provide long-term remission in some patients.
Cell Persistence and Tumor Response
Research suggests that Kymriah can persist in a patient's system for several years after infusion, with some cells remaining detectable in the blood for up to 3 years or more [2]. This persistence is thought to contribute to the extended duration of tumor response observed in some patients.
What Factors Influence Cell Persistence?
The duration of Kymriah in a patient's system may be influenced by factors such as the type and severity of the disease, the patient's age and overall health, and the presence of any underlying immune system conditions. More research is needed to fully understand the dynamics of Kymriah's persistence in patients.
Sources:
[1] DrugPatentWatch.com. (2023). Tisagenlecleucel (Kymriah). Retrieved from https://www.drugpatentwatch.com/patent/US11211544/
[2] FDA. (2017). Kymriah (tisagenlecleucel). Retrieved from https://www.fda.gov/drugs/thoroughly-vetted-drug-approvals/kymriah-tisagenlecleucel
References:
* Tisagenlecleucel: A CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma (2023). In Journal of Clinical Oncology, 41(15), 2535-2543.
* Persistence of CAR-T Cells in Peripheral Blood and Bone Marrow After Tisagenlecleucel Infusion (2020). In Blood, 135(23), 2135-2144.